Résumé :
|
[BDSP. Notice produite par INIST-CNRS ER0x8tsE. Diffusion soumise à autorisation]. The authors evaluated the association between receipt of measles-mumps-rubella (MMR) vaccine and asthma-like disease in early childhood in a Danish nationwide cohort study (N=871,234). Two outcomes were included : hospitalizations with asthma diagnoses and use of anti-asthma medications (for a subset of the cohort only). Poisson regression was used to estimate rate ratios according to vaccination status. MMR-vaccinated children were less often hospitalized with an asthma diagnosis (rate ratio (RR)=0.75,95% confidence interval (Cl) : 0.73,0.78) and used fewer courses of anti-asthma medication (RR=0.92,95% Cl : 0.91,0.92) than unvaccinated children. This "protective" effect of MMR vaccine was more pronounced for hospitalizations with severe asthma diagnoses (status asthmaticus : RR=0.63,95% Cl : 0.49,0.82) and use of medication that was highly specific for asthma (long-acting bêta2-agonist inhalant : RR=0.68,95% Cl : 0.63,0.73). MMR vaccine was not negatively associated with anti-asthma medications often used for wheezing illnesses in early childhood (systemic bêta2-agonist : RR=1.02,95% Cl : 1.01,1.02). These results are compatible not with an increased risk of asthma following MMR vaccination but rather with the hypothesis that MMR vaccination is associated with a reduced risk of asthma-like disease in young children.
|